ARCHIVES

Two Phase II Ibrutinib Studies Presented to EHA Demonstrate Efficacy as a Monotherapy

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Abraxane Improves Progression-Free Survival Compared to Decarbazine In Stage IV Disease

November 30, 2012

Dietary Interventions Reduce Breast Cancer Risk In Trials

May 27, 2005

In Congress: Senate Resolution Includes $15 Billion For NIH In FY99

April 10, 1998

Micafungin Bests Fluconazole In Phase III Antifungal Trial

November 29, 2002

Competition Developing For Three New Regional Cooperative Group Awards; RFA Within Two Months

December 12, 1980

Requiring Survival Data Was Logical In 1950s, Not Today, Broder Says

January 13, 1989